Raymond James Archives

Markets

Raymond James upgrades Alpha Cognition to outperform; PT to $2

Raymond James upgraded Alpha Cognition (CSE:ACOG) to “outperform” from “market perform” and raised its price target to C$2 from C$1 with the company’s PDUFA date less than 2 weeks away (July 27th). The stock closed at...

July 15, 2024

Markets

RJ ups Profound Medical to strong buy

Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...

September 18, 2023

Executive Moves

Veteran investment banker Jed Cohen joins Raymond James

Seasoned investment banker Jed Cohen has joined Raymond James as a managing director of its healthcare investment banking practice. The strategic hire underscores the firm’s continuing commitment to expanding the sector...

July 14, 2023

Markets

RJ starts WELL Health at OP; PT $8.50 (Canadian)

Raymond James initiated coverage of WELL Health Technologies (TSX:WELL) with an “outperform” rating and price target of $8.50 (Canadian). The stock closed at $5.46 on April 27. WELL Health operates a hybrid care...

April 28, 2023

Markets

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

In a new report, Raymond James analyst, Rahul Sarugaser, Ph.D., outlined his five main takeaways from presentations from four key opinion leaders – Yale, UCLA, Mayo Clinic and WellSpan Health – about their clinical...

March 15, 2023

Markets

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...

March 8, 2023

Executive Moves

Raymond James adds 3 senior bankers to healthcare practice

Raymond James Ltd. (CNW Group/Raymond James Ltd.) Raymond James again expanded its healthcare investment banking practice with the addition of three senior bankers. Joining the firm as managing directors are Jeff...

January 12, 2023

Markets

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James raised its price target for Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) to $14 from $10, and reiterated its “outperform” rating after the company acquired Great Elm Healthcare for about $80-million. The...

January 4, 2023

Markets

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James analyst, Rahul Sarugaser, Ph.D., outlined a series of potential catalysts for Profound Medical (NASDAQ:PROF; TSX:PRN), through 2023 and 2024 as it continues to commercialize its TULSA-PRO medical device to...

December 19, 2022

Markets

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James initiated coverage of POINT Biopharma (NASDAQ:PNT) with an “outperform” rating and price target of $10 target. The stock closed at $6.61 on Dec. 13. POINT is a precision oncology company focused on the...

December 14, 2022

Tag - Raymond James

Raymond James upgrades Alpha Cognition to outperform; PT to $2

RJ ups Profound Medical to strong buy

Veteran investment banker Jed Cohen joins Raymond James

RJ starts WELL Health at OP; PT $8.50 (Canadian)

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James adds 3 senior bankers to healthcare practice

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James starts POINT Biopharma at OP; PT $10

General

More